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ABSTRACT			Introduction		Amyotrophic	lateral	sclerosis	(ALS)	or	motor	neuron	disease	is	a	rapidly	progressive	neurodegenerative	disorder.		The	primary	involvement	is	of	motor	neurons	in	the	brain,	spinal	cord,	and	peripherally.		There	is	secondary	weakness	of	muscles,	and	primary	involvement	of	other	brain	regions,	especially	involving	cognition.		Sources	of	data		Peer-	reviewed	journal	articles	and	reviews.		PubMed.gov		Areas	of	agreement			The	pathogenesis	of	ALS	remains	largely	unknown.		There	are	a	wide	range	of	potential	mechanisms,	related	to	neurodegeneration.		An	increasing	number	of	genetic	factors	are	recognized.		Areas	of	controversy		
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There	remains	controversy,	or	lack	of	knowledge,	in	explaining	how	cellular	events	manifest	as	the	complex	human	disease.	There	is	controversy	as	to	how	well	cellular	and	animal	models	of	disease	relate	to	the	human	disease.			Growing	points		Large	scale	international	collaborative	genetic	epidemiological	studies	are	replacing	local	studies.	Therapies	related	to	pathogenesis	remain	elusive,	with	the	greatest	advances	to	date	relating	to	provision	of	care	(including	multidisciplinary	management),	and	supportive	care	(nutrition	and	respiratory	support).		Areas	timely	for	developing	research		The	identification	of	C9orf72	hexanucleotide	repeats	as	the	most	frequent	genetic	background	to	ALS,	and	the	association	with	frontotemporal	dementia,	gives	the	potential	of	a	genetic	background	against	which	to	study	other	risk	factors,	triggers,	and	pathogenic	mechanisms,	and	to	develop	potential	therapies.
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INTRODUCTION		Amyotrophic	lateral	sclerosis	(ALS)	or	motor	neuron	disease	in	its	purest	form	is	a	readily	identified	clinical	condition.		It	is	a	rapidly	progressive	degeneration	of	upper	and	lower	motor	neurons,	that	results	in	weakness	and	wasting	of	muscle	in	the	arms,	leg,	trunk	and	bulbar	region.		There	is	associated	spasticity	in	the	arms,	legs	and	bulbar	regions.		Clinical	symptoms	include	loss	of	ambulation,	loss	of	arm	and	hand	function,	difficulty	with	speech	and	swallowing,	and	breathlessness.		Aspiration	pneumonia	and	respiratory	insufficiency	are	common	terminal	events.		The	characteristic	onset	is	from	symptoms	and	signs	at	a	single	site,	progressing	to	contiguous	regions,	often	leading	to	death	within	3	to	5	years	of	symptom	onset.		A	wider	range	of	presentation	is	recognized,	and	supported	on	a	pathological	and	genetic	basis.		In	particular	the	recognition	of	cognitive	dysfunction,	and	specifically	an	association	with	behavioural	variant	frontotemporal	dementia	(FTD).				Despite	increasing	recognition	of	genetic	and	pathological	contributions,	the	details	of	pathogenesis	remain	unclear.		Disease	modifying	therapy	is	limited	to	riluzole	(if	nutrition	and	respiratory	support	are	excluded),	and	there	is	no	curative	treatment.		Key	overriding	considerations	in	pathogenesis	include	the	contribution	of	environment	and	genetics,	and	the	relatively	selective	vulnerability	of	motor	neurons.		The	pathogenesis	may	be	conceptualized	to	have	a	background	vulnerability,	a	trigger	factor,	a	propagation	mechanism,	and	
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the	final	manifestations	of	the	clinical	disease	ALS.		Each	of	these	may	involve	different	factors.		This	review	explores	recent	evidence	adding	to	our	understanding	of	ALS	pathogenesis,	but	is	inevitably	not	comprehensive,	the	evidence	may	be	conflicting,	and	there	remains	no	fully	confirmed	pathogenic	mechanism.		The	references	tend	to	be	reviews,	where	the	prime	publications	in	the	field	may	be	obtained,	and	are	not	comprehensive.		Using	statistical	modelling,	a	six	step	process	has	been	identified	as	underlying	ALS	pathogenesis,	with	conceptual	similarities	to	cancer	pathogenesis.1		The	findings	at	the	late	stage	of	disease	probably	do	not	represent,	and	may	mask,	factors	earlier	in	the	disease,	which	predates	onset	of	any	symptoms	and	signs.			
PATHOGENESIS	OF	ALS		
1.		Background	vulnerability		Epidemiological	studies	of	ALS	show	a	worldwide	incidence	of	2-3	per	year	per	100,000	population	over	the	age	of	15	years,	and	an	overall	lifetime	risk	of	developing	ALS	of	1:350	for	men	and	1:400	for	women.		Risk	increases	with	age,	with	a	peak	around	75	years.2		Around	10%	of	individuals	have	a	family	history	of	ALS,	and	other	neurodegenerative	conditions	including	FTD.		A	study	of	twin	data	suggested	that	heritability	contributes	60%	to	the	risk	of	developing	ALS,	and	environment	40%3,	but	an	analysis	from	three	genome-wide	association	studies	found	a	lower	heritability	of	21%.	4		
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	Genes		An	increasing	number	of	genes	are	recognized	as	associated,	and	causative	of	ALS.5		The	most	common	are	C9orf72,	SOD1,	TARDBP,	and	FUS.		Commonly	proposed	pathogenic	mechanisms	include	RNA	metabolism,	and	protein	metabolism	(Figure	1,	Table	1).6			
C9ORF72		C9orf72	is	the	most	frequent	genetic	change	identified	in	patients	with	ALS.		It	is	also	specifically	found	in	patients	with	FTD.		Expansions	are	found	in	around	39%	of	familial	ALS	patients,	and	7%	of	apparently	sporadic	cases,	of	European	ancestry7,	but	with	significant	differences	between	populations.		For	example,	a	study	of	563	patients	with	ALS	in	Japan	identified	expansions	in	0.4%	of	sporadic	and	0%	of	familial	ALS	patients8,	and	in	less	than	1%	of	Chinese	sporadic	ALS	patients.9		Patients	with	ALS	often	display	cognitive	changes,	and	there	is	an	overlap	between	ALS	and	FTD.10		Behavioural	variant	FTD	is	the	most	common	clinical	syndrome,	with	features	of	apathy,	disinhibition,	socially	inappropriate	behaviour,	abnormal	eating	behaviours,	loss	of	empathy,	and	perseverative,	stereotyped	or	obsessive-compulsive	behaviour.		Hallucinations	and	delusions	may	occur.		Within	a	family	some	individuals	may	have	ALS,	and	some	FTD.		The	genetic	feature	is	a	hexanucleotide	repeat	of	GGGGCC,	either	in	the	promotor	or	intron	1	of	the	gene.		The	normal	range	of	repeats	is	uncertain,	but	usually	
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considered	up	to	20	repeats,	while	patients	with	ALS	and	FTD	usually	have	repeats	of	several	hundred	to	thousands.		Inheritance	is	autosomal	dominant.		There	is	no	clear	intergenerational	anticipation,	however,	short	expansions	(45-78	repeats)	have	been	associated	with	age	at	onset	and	C9orf72	families	displayed	possible	anticipation.	11	There	is	TDP-43	pathology.		There	are	also	p62-positive	neuronal	cytoplasmic	inclusions,	composed	of	dipeptide	repeat	proteins	(DPR)	formed	by	translation	from	the	abnormally	expanded	repeat	in	C9orf72.		A	particular	feature	of	the	C9orf72	expansion	is	repeat-associated	non-ATG	(RAN)	translation,	that	can	occur	in	all	six	sense	and	antisense	frames,	resulting	in	five	different	DPR	proteins.12				The	mechanisms	of	toxicity	remain	unclear,	but	a	richer	understanding	is	gradually	being	achieved.13			
SOD1		Copper	zinc	superoxide	dismutase	(SOD1)	was	the	first	genetic	cause	of	ALS	to	be	identified,	in	1993.14		Mutations	are	commonly	estimated	to	be	present	in	around	20%	of	familial	patients,	and	1%	of	apparently	sporadic.			The	frequency	will	vary	between	populations,	and	in	an	Italian	population	SOD1	mutations	were	identified	in	14%	of	familial	ALS	patients.15			Founder	haplotypes	may	have	significant	effects	on	frequency.		The	mutations	are	predominantly	point	mutations.		Inheritance	is	autosomal	dominant.		There	are	over	170	different	genetic	alterations	recognized,	although	many	of	these	are	private	to	individuals,	and	causation	may	be	difficult	to	prove	outside	large	families.		Disease	pathogenesis	remains	uncertain,	but	an	unusual	feature	is	the	absence	of	TDP-43	
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pathology	now	thought	to	be	typical	of	ALS	otherwise.		The	disease	mechanism	appears	to	be	a	gain-of-function,	and	not	a	loss	of	enzyme	function.		Protein	misfolding,	and	oxidative	stress	are	amongst	the	possible	mechanisms.		
	
TARDBP		TAR	DNA-binding	protein	43	(TARDBP/TDP-43)	mutations	are	found	in	around	5%	of	patients	with	familial	ALS.16		Inheritance	is	autosomal	dominant.		TDP-43	is	the	protein	typically	found	in	the	tau-	and	alpha-synuclein-negative,	ubiquinated,	cytoplasmic	inclusions	or	aggregates	found	in	ALS,	and	a	subset	of	FTD.		TDP-43	is	an	RNA	and	DNA	binding	protein	that	regulates	transcription,	mRNA	splicing,	transport	and	stability.		Current	pathogenic	concepts	include	a	gain	of	function	toxicity	of	mutant	TDP-43	in	disruption	of	stress	granules,	that	aggregate	and	form	cytoplasmic	ubiqutinated	protiein	inclusions.		Loss	of	function	may	occur	through	depletion	of	TDP-43	in	the	nucleus	of	the	motor	neuron,	when	the	TDP-43	is	included	in	the	cytoplasmic	ubiquitinated	protein	inclusions	induced	by	mutant	TARDBP,	resulting	in	dysregulation	of	nuclear	RNA	metabolism.			
FUS		Fused	in	sarcoma	/	translated	in	liposarcoma	(FUS)	is	also	found	in	around	5%	of	patients	with	familial	ALS.17		FUS	is	a	nucleoprotein,	that	regulates	RNA	and	DNA	binding,	gene	expression,	and	mRNA	splicing.		FUS	colocalises	with	TDP-43	
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to	stress	granules	in	the	motor	neuron.		Potential	pathogenic	mechanisms	are	similar	to	those	of	TDP-43.		
Other	genes		Rarer	genetic	causes	of	ALS	include	vehicle-associated	membrane	protein	B	(VAPB);	valosin-containing	protein	(VCP)	(also	found	in	patients	with	inclusion	body	myopathy,	Paget	disease	and	FTD	(IBMPFD).		Ubiquilin-2	(UBQLN2)	is	a	rare	form	of	X	linked	ALS.		Alsin	(ALS2)	is	associated	with	atypical	juvenile	forms	of	ALS,	with	recessive	inheritance.		Other	genes	include	optineurin	(OPTN),	and	spastacin	(SPG11).18		The	role	of	genes	such	as	angiogenin	(ANG)	remains	controversial.		Other	genes	are	being	recognized	as	risk	factors	for	ALS,	including	heavy	chain	neurofilament	(NEFH),	and	progranulin	(GRN).		There	are	a	number	of	reports	of	an	intermediate	length	expansion	of	the	CAG	repeat	in	the	ataxin-2	gene	(ATXN2),	that	with	more	than	34	expansions	cause	spinocerebellar	ataxia	type	2	(SCA2),	with	repeat	numbers	of	27-33	found	in	5%	of	patients	with	ALS.		Next-generation	sequencing	technologies	allow	rapid	and	relatively	inexpensive	sequencing	of	ALS-related	genes.		Sequencing	17	known	genes,	64%	of	familial	and	28%	of	sporadic	ALS	patients	had	potentially	pathogenic	novel	or	rare	coding	variants.		4%	of	patients	had	variants	in	more	than	one	gene.		This	gives	further	insight	to	the	oligogenic	pathogenesis	of	ALS,	and	complicates	the	clinical	interpretation	of	genetic	analysis	of	patients.19,20	
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	Epigenetics		Epigenetics	provides	a	potential	link	between	environmental	and	genetic	pathogenic	mechanisms.		Environmental	factors	switch	genes	on	and	off	and	affect	how	cells	express	genes,	rather	than	changes	in	a	DNA	sequence.		This	includes	DNA	methylation,	histone	modification,	and	noncoding	RNAs	such	as	microRNA	(miRNA).		A	range	of	epigenetic	mechanisms	and	findings	have	been	reviewed.21			
2.		Trigger	factors	
	Investigating	the	earliest	stages	of	ALS	in	patients	is	difficult,	but	pathological	studies	point	to	a	focal	onset,	occurring	at	an	apparently	random	location,	and	progressing	contiguously.22		This	may	be	an	explanation	for	the	range	of	clinical	presentations,	i.e.	ALS	or	progressive	muscular	atrophy	(PMA);	bulbar	or	limb	onset;	ALS	or	FTD;	on	the	background	in	some	instances	of	a	strong	genetic	mutation.		Inevitably,	autopsy	data	represents	the	end	stage	of	the	disease,	and	it	is	difficult	to	extrapolate	to	the	onset	of	disease.		An	alternative	theory	to	contiguous	propagation	is	a	network	propagation	i.e.	through	axonal	and	synaptic	connections.23		Protein	misfolding	and	templating	of	pathogenic	proteins,	a	prion-like	mechanism,	is	currently	being	explored	in	ALS	and	many	other	neurodegenerative	diseases.		An	EMG	approach	to	determining	
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propagation	did	not	support	contiguous	spread,	and	suggested	“multifocal	hits	with	local	propagation”.24			Imaging	studies	are	becoming	increasingly	sophisticated.		Longitudinal	analysis	of	MRI	scans	of	patients	with	ALS	identified	a	core	white	matter	pathology	–	that	appeared	to	be	stable	–	and	reflecting	upper	motor	neuron	clinical	features,	but	with	a	progressive	grey	matter	pathology	that	was	widespread,	and	interpreted	as	representing	a	widespread	cortical	network	degeneration.25		This	has	implications	for	developing	and	monitoring	potential	therapies.		Epidemiological	studies	are	difficult	to	perform	in	ALS,	and	some	results	are	contradictory.		Physical	activity,	including	sports	and	repeated	traumatic	events	was	not	found	to	be	a	risk	factor	for	ALS,	and	could	be	protective.26		Repeated	head	trauma	was	associated	with	risk	of	ALS,20	and	intriguingly	TDP-43-positive	inclusions	have	been	identified	in	the	frontotemporal	brain	and	spinal	cord	of	people	with	chronic	traumatic	encephalopathy.27		There	are	studies	suggesting	associations	with	football,	smoking,	heavy	metals,	pesticides	and	chemicals,	occupation,	military	service,	electric	shock,	geography,	and	cyanotoxins,	but	the	evidence	is	not	clear,	and	proof	of	causation	not	available.2,28		
	
	
3.		Propagation	
	There	are	a	wide	range	of	potential	pathogenic	mechanisms,	reflecting	the	range	and	fashion	of	mechanisms	of	neurodegenration.		A	pathway	analysis	of	results	
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from	two	ALS	genome-wide	association	studies	(GWAS)	supported	shared	genetic	pathways	with	Alzheimer’s	disease	and	Parkinsons’s	disease.29		A	range	of	neurodegenerative	diseases,	beyond	ALS	an	FTD,	are	more	frequent	than	expected	in	individuals	with	large	C9orf72	hexanucleotide	repeat	expansions.30		It	remains	probable	that	ALS	is	the	final	end	point	of	a	number	of	different	pathogenic	pathways,	converging	at	the	clinical	presentation.		Different	individuals	may	have	contributions	from	different	pathways,	as	supported	by	the	range	of	potential	genetic	backgrounds	(Figure	2).31		RNA	processing		The	dominant	theory	of	ALS	pathogenesis	at	present	relates	to	RNA	processing.		In	particular	this	is	due	to	the	finding	of	TDP-43	pathology	in	most	ALS	cases,	and	genes	including	TARDBP	and	FUS	being	genetic	causes	of	ALS.		These	genes	are	both	involved	in	pre-mRNA	splicing,	RNA	transport	and	RNA	translation.		The	pre-mRNA	containing	the	C9orf72	repeat	expansion	may	sequester	nuclear	RNA-binding	proteins	that	are	then	unavailable	for	correct	splicing	of	other	mRNAs.		MicroRNAs	(miRNA)	are	dysregulated	in	FTD-ALS,	and	may	be	disrupted	by	C9ORF72,	TDP-43,	FUS,	and	other	genetic	pathways	associated	with	ALS.32		Protein	aggregation		Intraneuronal	protein	aggregates,	including	TDP-43,	FUS,	and	SOD1	are	well	recognised	in	pathological	studies	of	patients	with	ALS,	and	in	animal	models	of	
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the	disease.		It	is	proposed	that	the	aggregates	disturb	normal	protein	homeostasis	(proteostasis)	and	induce	cellular	stress.		The	aggregates	may	sequester	RNA	and	other	proteins	essential	for	normal	cellular	function.		The	physical	effect	of	the	aggregates	may	cause	impaired	axonal	transport.		There	may	also	be	impaired	protein	degradation,	related	to	failure	of	ubiquitin-dependent	protein	degradation.		Energetic	exhaustion	of	motor	neurons	may	relate	to	the	turnover	of	misfolded	proteins.33		Oxidative	stress		Oxidative	stress	is	implicated	in	the	pathogenesis	of	neurodegenerative	diseases,	including	ALS.		When	first	identified,	SOD1	mutations	suggested	a	possible	primary	role	in	oxidative	stress	related	to	the	superoxide	dismuatase	function.		This	does	not	appear	to	be	the	case,	and	oxidative	stress	is	probably	a	secondary	component	of	pathogenesis.		Mitochondria		Mitochondrial	dysfunction	is	a	common	feature	of	many	neurodegenerative	disorders.		There	is	a	body	of	evidence	to	support	impaired	mitochondrial	bioenergetics,	but	also	possible	roles	related	to	mitophagy	and	quality	control34,	endoplasmic	reticulum	stress	and	calcium	signalling.35		Mutant	SOD1	accumulates	in	the	intermembrane	space	of	mitochondria,	leading	to	mitochondrial	dysfunction.36		Mitochondrial	dysfunction	has	been	hypothesized	to	explain	a	range	of	clinical	features	of	ALS,	including	motor	neuron	
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hyperexcitability,	fasciculations,	and	differential	motor	neuron	vulnerability.37	Mutations	of	the	CHCHD10	gene	have	been	identified	in	patients	with	ALS.		CHCHD10	is	a	mitochondrial	protein	located	in	the	intermembrane	space	and	enriched	at	cristae	junctions.		The	phenotype	of	the	patients	included	FTD.38		Excitotoxicity		Glutamate	excitotoxicity	has	long	been	implicated	in	ALS	pathogenesis.		This	was	supported	by	neurochemistry	studies,	and	is	a	potential	explanation	of	selective	neuronal	vulnerability.		This	was	the	basis	of	trialling	riluzole	as	a	treatment	for	ALS,	as	a	glutamate-release	inhibitor.		The	mechanism	of	riluzole	is	unclear,	but	also	has	an	effect	on	sodium	channels,	and	calcium-activated	potassium	channels.39		Growth	factors		Growth	factors	are	essential	in	neuronal	growth,	maintenance	and	repair.		In	previous	decades	there	was	interest	related	to	their	potential	therapeutic	use,	but	without	success.		There	is	current	interest	in	a	Nogo-A	monoclonal	antibody,	to	encourage	nerve	growth.40		Nogo-A	is	a	neurite	outgrowth	inhibitor	that	has	been	shown	to	be	overexpressed	in	skeletal	muscle	in	ALS.		Axoplasmic	flow		
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A	unique	feature	of	spinal	nerves	is	the	long	axon.		Essential	to	the	maintenance	of	the	axon	structure,	and	transport	of	proteins,	mitochondria,	and	other	important	traffic	between	the	nucleus	and	cell	body,	and	the	neuromuscular	junction	or	other	synapses,	are	neurofilaments.		Neurofilaments	are	the	most	abundant	cytoskeletal	protein	in	motor	neurons,	and	determine	axon	diameter.		There	are	well	demonstrated	defects	of	axonal	transport	in	animal	models,	and	human	pathological	findings	of	impaired	transport.		In	the	majority	of	patients	disturbed	axoplasmic	flow	is	probably	a	secondary,	but	important,	effect.		Templating		The	concept	of	a	proteinopathy,	or	protein-misfolding	disorder,	is	an	attractive	hypothesis	for	neurodegenerative	disorders,	including	ALS.41,42		Inclusions	or	misfolded	proteins	are	clearly	a	common	feature	of	ALS	pathology,	whatever	the	genetic	or	environmental	basis.		The	protein	misfolding,	and	templating,	could	be	an	explanation	for	contiguous	propagation.		Calling	ALS	a	prion	disease	has	probably	confused	the	issue,	and	templating	may	be	a	preferred	term,	as	this	is	not	proposed	to	be	a	prion	protein.		There	is	no	evidence	of	infectivity	of	ALS,	although	conjugal	cases	occur	rarely.		If	templating	is	a	propagation	mechanism,	this	should	be	amenable	to	potential	therapeutic	approaches.		Inflammatory		An	inflammatory	basis	to	neurodegeneration	is	well	recognised.		In	ALS	there	is	an	understandable	focus	on	the	motor	neurons,	but	evidence	exists	that	this	is	a	
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non-cell-autonomous	disease,	and	non-neuronal	cells,	in	particular	microglia	may	have	an	important	role	in	pathogenesis.		This	is	a	complex	area,	and	much	of	the	data	is	based	on	animal	models.43		Nevertheless,	inflammatory	pathways	are	a	potential	therapeutic	target,	especially	in	influencing	rate	of	progression.44		Myogenic		There	has	been	a	long	standing	debate	between	the	primary	neurogenic	–	and	now	motor	cortex	and	networks,	and	the	primary	myogenic	–	or	neuromuscular	junction	–	origin	of	ALS.		The	potential	pathogenesis	of	ALS	is,	at	present	broad.		For	the	patient	it	is	the	muscle	weakness	that	causes	major	disability,	and	if	the	muscle	weakness	could	be	prevented	or	reversed,	much	of	the	disability	would	resolve.		Muscle	weakness	unifies	the	wider	presentations	of	spinal	muscular	atrophy,	spinobulbar	muscular	atrophy,	and	the	other	age-related	cachexias.		Growth	factors,	axonal	transport,	mitochondrial	dysfunction,	and	other	factors	impact	on	this	potential	cause,	contributor	or	consequence.45,46				A	number	of	genes	that	cause	ALS	also	affect	muscle,	including	VCP,	MATR3,	and	CHCHD10,	with	differing	phenotypes.		VCP	(Valosin-containing	protein)	mutations	may	present	as	ALS	(with	or	without	frontotemporal	dementia),	Charcot-Marie-Tooth	disease	type	2Y,	or	inclusion	body	myopathy	with	early-onset	Paget	disease	and	frontotemporal	dementia.47		MATR3	(Matrin	3)	mutations	may	present	as	ALS,	or	a	distal	myopathy.48		CHCHD10	(Coiled-coil-helix-coiled-coil-helix	domain-containing	protein	10)	mutations	may	present	as	
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ALS	and/or	frontotemporal	dementia,	spinal	muscular	atrophy	Jokela	type,	or	an	autosomal	dominant	isolated	mitochondrial	myopathy.38	
	
4.		Final	clinical	manifestations		The	final	clinical	manifestations	relate	to	systems	biology,	and	difficulties	in	understanding	relate	to	the	limited	knowledge	we	have	of	the	human	nervous	system	in	health	and	disease.	A	key	question	remains	as	to	why	the	motor	neurons	are	selectively	involved.		The	presentation	of	limb	weakness,	muscle	wasting,	fasciculation,	spasticity,	and	difficulties	with	speech	and	swallowing	are	more	readily	understood.49.				Genotype-phenotype	correlations	are	difficult	to	define,	especially	given	the	rarity	of	some	specific	mutations.		There	is	an	observation	that	patients	with	SOD	mutations	have	predominantly	lower	limb	onset,	and	with	TARDP	mutations	have	upper	limb	onset.		Patients	with	FUS	mutations	have	an	earlier	age	of	onset,	and	shorter	lifespan.50		
CONCLUSION		Therapeutic	implications		The	lack	of	a	clear	pathogenesis	has	hampered	the	development	of	an	effective	therapy.	On	the	other	hand,	the	abundance	of	potential	mechanisms	has	led	to	many	attempts	at	treatments	which	usually	fail	in	clinical	trials.	51		The	potential	
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reasons	for	failure	are	many,	and	include	the	wrong	target,	inappropriate	pharmacodynamics,	route	of	administration,	outcome	measures,	publication	bias,	and	the	probability	that	there	may	be	different	pathogenic	mechanisms	at	play	in	different	patients.		The	genetics	of	ALS	has	shown	that	this	represents	a	plethora	of	diseases,	rather	than	a	single	biological	entity.		The	relevance	of	therapeutic	benefit	in	cell	and	animal	models	of	ALS	remains	uncertain.52,53		In	one	individual	there	may	be	different	mechanisms	active	at	once,	or	at	different	stages	of	the	disease.		Upstream	targets	include	genetic	mechanisms	such	as	SOD1.		21	ALS	patients	with	a	range	of	SOD1	mutations	participated	in	a	Phase	1	study	of	intrathecal	antisense	oligonucleotide	ISIS	333611.54		There	are	more	than	150	different	SOD1	mutations,	some	family	specific.		The	antisense	oligoneucleotide	used	in	this	study	was	designed	to	activate	RNase	H	mediated	degradation	of	all	SOD1,	rather	than	a	specific	mutant,	allowing	for	a	wider	potential	use,	and	possibility	of	an	effective	clinical	trial.		C9orf72	creates	the	potential	for	a	more	generic	gene	therapy.55		Downstream	targets,	if	identified,	allow	a	more	universal	therapy,	and	may	be	common	to	other	neurodegenerative	diseases.		ATXN2	(ataxin)	remains	another	potential	therapeutic	target.56		Diagnostic	implications		The	identification	of	significant	genetic	contributions,	allows	genetic	definition	of	a	disease.		This	has	widened	our	understanding	of	clinical	presentations,	including	more	focal,	slowly	progressive,	and	atypical	forms,	that	would	not	fit	classical	diagnostic	criteria.		
	 Orrell	-	19	-	
Genetic	implications		The	identification	of	genes	has	the	potential	for	greater	understanding	of	ALS,	and	prevention	or	treatment	in	the	future.		At	present,	however,	there	is	uncertainty	of	the	significance	of	many	reported	mutations,	given	the	age-dependent	nature	of	ALS,	the	incomplete	penetration	of	causal	genes,	and	varying	clinical	presentations,	including	apparently	different	neurodegenerative	diseases	with	C9orf72.		There	is	much	discussion	of	how	best	to	approach	this	from	a	clinical	point	of	view,	and	there	are	a	range	of	theories.57		At	one	extreme	the	identification	of	a	gene	may	be	helpful	for	decision	making	in	families	with	clear	multigeneration	autosomal	dominant	inheritance,	such	as	some	families	with	SOD1	mutations.		Given	the	potential	future	developments	related	to	our	understanding	of	ALS	pathogenesis,	genetics,	and	therapy,	there	is	a	strong	argument	of	preserving	DNA	from	affected	individuals	for	future	research.		Some	suggest	that	all	patients	with	ALS	should	be	tested	for	all	genes	and	be	provided	with	the	relevant	information,	with	appropriate	explanation	and	support.		Others	suggest	that	only	patients	with	a	clear	family	history	of	ALS	should	be	offered	the	possibility	of	genetic	testing.		This	is	further	complicated	by	the	current	availability	of	laboratory	testing	for	genes,	and	the	associated	cost.		Advances	in	genetic	technology	are	rapidly	solving	this	issue,	with	large	numbers	of	genes	being	sequenced	at	a	relatively	low	cost.		There	is	a	range	of	clinical	views	on	how	to	approach	this,	and	a	broad	view	is	required.58		We	have	achieved	the	situation	where	there	are	a	large	number	of	potential	genes	for	ALS,	some	individuals	may	have	more	than	one	gene,	some	none,	there	is	variable	penetrance,	and	we	do	not	know	how	these	mutations	cause	the	disease.		From	
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being	potentially	potent	in	determining	outcome,	genetic	analysis	is	now	but	another	risk	factor	–	although	not	to	be	dismissed.		The	situation	would	be	transformed	if	we	had	preventive	or	curative	approaches	based	on	this	knowledge.					
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		Table	1		Genes	implicated	in	causation	of	ALS.			(Many	of	these	are	very	rare	causes,	and	the	function	given	is	putative.5			RNA	metabolism		 C9ORF72		 TARDBP		 FUS		 hnRNPA1		 hnRNPA2B1		 SETX		 TAF15		 ANG		 	Antioxidant		 SOD1		Cellular	transport		 ALS2		 VAPB		Protein	metabolism	
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	 SQSTM1		 VCP		 UBQLN2		 OPTN		Axonal	outgrowth		 PFN1		Glutamatergic	signaling		 DAO			Genes	that	appear	to		modify	ALS	risk	or	progression		RNA	metabolism		 ATXN2	Cytosketal	protein		 NEFH	Protein	metabolism		 GRN	Angiogenesis		 VEGF	Neurotransmission		 UNC13A		
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Figure		1.						Approximate	frequency	of	gene	mutations	in	familial	ALS	(other	known	affected	family	members)	and	apparently	sporadic	ALS	(no	other	known	family	members).					
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		Figure	2.		An	illustration	of	the	complexity	of	ALS	pathogenesis.		The	inner	circle	includes	the	associated	genes	with	highest	frequency	(C9orf72,	SOD1,	TDP-43/TARDBP,	and	FUS).		The	second	order	ring	includes	the	large	number	of	genes	with	a	lower	frequency	of	association.		The	third	order	ring	includes	the	possible	pathogenic	mechanisms	that	are	hypothesised	to	be	associated	with	these	genes.		The	outer	ring	includes	the	other	diseases	that	may	be	associated	with	these	genes.		The	complex	relationship	between	genes	associated	with	neurodegeneration,	mechanisms	of	neurodegeneration,	and	clinical	disease	phenotypes	is	apparent.		Red	=	major	genes;	Black	=	minor	genes;	Orange	=	disease	mechanisms;	Blue	=	associated	diseases.		Mechanistic	connections	are	illustrated	by	orange	lines,	and	disease	associations	by	blue	lines.									
